Chronic incontinence is a significant clinical issue for the elderly and is a prevalent consequence of several neurological illnesses. Urinary incontinence may be the deciding factor in a patient's need for long-term institutional care. Catheter associated urinary tract infections (CAUTIs) are prevalent hospital-acquired infections that continue to pose a considerable medical and financial burden on the healthcare system.
External urinary catheters (EUC) are collection devices or systems (referred to as external urine collection devices [EUCD] in the UroToday reference centre) for collecting and containing urine away from the perineum or penis into a drainage suction or bag via tubing into a container. A EUCD cannot be implanted in the kidney like a nephrostomy tube or stent, or in the bladder or urethra like a catheter for intermittent drainage or an indwelling (Foley) device. It is used to drain urine in those who have urinary incontinence and is attached to the genitalia or pubic area. As the device is connected to the body, they are often referred to as “bodyworn products.” The growth in the occurrence of urine incontinence in the global female population is one of the key factors boosting the growth of the external urine management products market.
Newest Insights in the External Urine Management Products Market
Numerous people with illnesses like bladder dysfunction, such as cystitis, urinary incontinence, UI, benign prostatic hyperplasia, and kidney stones have benefited from recent advancements in the field of external urine management products. As per a report by Research Dive, the global external urine management products market is expected to surpass a revenue of $31,929.3 million in the 2022-2031 timeframe. The North America external urine management products market is expected to perceive dominant growth in the years to come. This is because the region has a gigantic demand for external urine management products owing to the increasing geriatric population, rising occurrence of disorders like urinary tract infection (UI), bladder obstruction, urine retention, and bladder cancer growth, and growing life expectancy in the region.
How are Market Players Responding to the Rising Demand for External Urine Management Products?
Market players are greatly investing in pioneering research and inventions to cater for the rising demand for external urine management products. Some of the foremost players in the external urine management products market are Tilla Care, Inc., Teleflex, Inc., Men’s Liberty (BioDerm), Consure Medical, LLC, Boehringer Laboratories, Coloplast Corp., Hollister, Inc., B. Braun Melsungen AG, Sterimed Group, Cardinal Health, and others. These players are focused on planning and devising tactics such as mergers and acquisitions, collaborations, novel advances, and partnerships to reach a notable position in the global market.
- In January 2022, Stryker, a large international firm that manufactures medical technologies, in collaboration with clinicians, launched Sage PrimaFit® external urine management for the female anatomy to assist patients to receive better care.
- In September 2022, Sysmex, a suite of urinalysis, hematology, flow cytometry analyzers, and hemostasis for acute and non-acute healthcare settings, introduced a novel product for the field of urine sediment testing, the UF-1500 Fully Automated Urine Particle Analyzer.
- In November 2022, Ur24Technology, an external catheter system developed to enhance men's and women's quality of comfort, life, and self-esteem, launched the innovative "TrueClr" external catheter line.
COVID-19 Impact on the Global External Urine Management Products Market
The unpredicted rise of the coronavirus pandemic in 2020 has positively impacted the global external urine management products market. The COVID-19 virus primarily affects the elderly population and is more prevalent in persons with low or inadequate immunity. The need for external urine management solutions surged across several nations as hospital admission rates increased rapidly. After the World Health Organization (WHO) declared the COVID-19 outbreak as a pandemic, several well-established biopharmaceutical and pharmaceutical companies increased production and R&D efforts to create innovative ways to combat COVID-19. During the pandemic, several pharmaceutical and biotechnology corporations worked with their outsourcing businesses through partnerships, collaborations, and long-term agreements to speed up the R&D procedures. These measures are expected to propel the external urine management products market growth throughout the forecast period.